Last reviewed · How we verify
NCT07452211
First in Man Study of Pulsed Field Ablation System for the Treatment of Paroxysmal Atrial Fibrillation in 1 Patient
NA trial testing CardioPulsesTM pulsed field ablation system in Paroxysmal Atrial Fibrillation (PAF) in 10 participants. Completed in 10 April 2022.
10 April 2022
Quick facts
| Lead sponsor | Hangzhou Dinova EP Technology Co., Ltd |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 18 December 2020 |
| Primary completion | 10 April 2022 |
| Estimated completion | 10 April 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- CardioPulsesTM pulsed field ablation system
Conditions studied
- Paroxysmal Atrial Fibrillation (PAF) — all drugs for Paroxysmal Atrial Fibrillation (PAF) →
Sponsor
Hangzhou Dinova EP Technology Co., Ltd — full company profile →
Who can join
Adults 18 to 75, any sex, with Paroxysmal Atrial Fibrillation (PAF). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is the first in man study of CadioPulseTM ( pulsed field ablation system) developed and manufactured by Hangzhou Dinova EP Technology Co., Ltd, which can be used for Pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation. This study aims to initially verify the safety and efficacy of the device.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07452211
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CardioPulsesTM pulsed field ablation system
Trials testing the same drug.
- NCT05114954 — Evaluation of the Safety and Efficacy of the CardioPulseTM PuLsed fiEld Ablation SystEm in Patients With Paroxysmal Atri · NA · completed
Other recruiting trials for Paroxysmal Atrial Fibrillation (PAF)
Currently open trials in the same condition.
- NCT07298473 — Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sp · NA · recruiting
- NCT07421076 — Grid eXplore Mapping Study · NA · recruiting
Other Hangzhou Dinova EP Technology Co., Ltd trials
Trials by the same sponsor.
- NCT07036965 — Comparison of Different Pulsed Field Ablation Catheters in Atrial Fibrillation · NA · recruiting
- NCT06157437 — An Exploratory Study of Focal Pulse Ablation System in the Treatment of Atrial Arrhythmia · NA · recruiting
- NCT05360771 — Study on the Safety and Effectiveness of the SnowyTM PFO Closure System · NA · not yet recruiting
- NCT05731882 — First in Man Study of Left Atrial Appendage Pulsed Field Ablation Occluder · NA · unknown
- NCT05114954 — Evaluation of the Safety and Efficacy of the CardioPulseTM PuLsed fiEld Ablation SystEm in Patients With Paroxysmal Atri · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07452211 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hangzhou Dinova EP Technology Co., Ltd
- Last refreshed: 5 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07452211.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing